The co-morbidity burden of children and young adults with autism spectrum disorders.
The co-morbidity burden of children and young adults with autism spectrum disorders.
复制标题
DOI：
10.1371/journal.pone.0033224
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Churchill S
中科院分区：
文献类型：
--
作者：
Kohane IS;McMurry A;Weber G;MacFadden D;Rappaport L;Kunkel L;Bickel J;Wattanasin N;Spence S;Murphy S;Churchill S
使用电子健康记录自闭症谱系障碍（ASD）来评估儿童和年轻人ASD的共病负担。采用分布式查询系统对三家综合医院和一家儿科医院进行回顾性患病率研究。超过14,000名35岁以下的ASD患者以其合并症为特征，相反，测量了这些合并症中ASD的患病率。比较年轻（年龄<18岁）和老年（年龄18 - 34岁）ASD患者的合并症患病率。19.44%的ASD患者患有癫痫，而在整个医院人群中这一比例为2.19%(95%可信区间为百分比差异为13.58-14.69%)，2.43%的ASD患者患有精神分裂症，而在医院人群中这一比例为0.24% (95% CI 1.89-2.39%)，炎症性肠病（IBD）为0.83%，而在医院人群中这一比例为0.54% (95% CI 0.13-0.43%)，肠道疾病（无IBD）为11.74%，相比于4.5% (95% CI 5.72-6.68%)，中枢神经系统/颅异常为12.45%，相比于1.19% (95% CI 9.41-10.38%)，1型糖尿病（DM1） 0.79% vs 0.34% (95% CI 0.3-0.6%)，肌肉萎缩症0.47% vs 0.05% (95% CI 0.26-0.49%)，睡眠障碍1.12% vs 0.14% （95% CI 0.79-1.14%）。自身免疫性疾病（不包括DM1和IBD）无显著差异，分别为0.67%和0.68% （95% CI - 0.14-0.13%）。在0-17岁和18-34岁的人群中，有三种合并症显著增加（p<0.001）：精神分裂症（1.43%比8.76%）、I型糖尿病（0.67%比2.08%）、IBD(0.68%比1.99%)，而睡眠障碍、肠道疾病（无IBD）和癫痫没有显著变化。ASD的合并症包括在三级卫生中心的患者群体中ASD中明显过度代表的疾病状态。这种合并症的负担远远超出了发展医学中心的常规管理，需要广泛的多学科管理，付款人和提供者必须为此制定计划。
Use electronic health records Autism Spectrum Disorder (ASD) to assess the comorbidity burden of ASD in children and young adults. A retrospective prevalence study was performed using a distributed query system across three general hospitals and one pediatric hospital. Over 14,000 individuals under age 35 with ASD were characterized by their co-morbidities and conversely, the prevalence of ASD within these comorbidities was measured. The comorbidity prevalence of the younger (Age<18 years) and older (Age 18–34 years) individuals with ASD was compared. 19.44% of ASD patients had epilepsy as compared to 2.19% in the overall hospital population (95% confidence interval for difference in percentages 13.58–14.69%), 2.43% of ASD with schizophrenia vs. 0.24% in the hospital population (95% CI 1.89–2.39%), inflammatory bowel disease (IBD) 0.83% vs. 0.54% (95% CI 0.13–0.43%), bowel disorders (without IBD) 11.74% vs. 4.5% (95% CI 5.72–6.68%), CNS/cranial anomalies 12.45% vs. 1.19% (95% CI 9.41–10.38%), diabetes mellitus type I (DM1) 0.79% vs. 0.34% (95% CI 0.3–0.6%), muscular dystrophy 0.47% vs 0.05% (95% CI 0.26–0.49%), sleep disorders 1.12% vs. 0.14% (95% CI 0.79–1.14%). Autoimmune disorders (excluding DM1 and IBD) were not significantly different at 0.67% vs. 0.68% (95% CI −0.14-0.13%). Three of the studied comorbidities increased significantly when comparing ages 0–17 vs 18–34 with p<0.001: Schizophrenia (1.43% vs. 8.76%), diabetes mellitus type I (0.67% vs. 2.08%), IBD (0.68% vs. 1.99%) whereas sleeping disorders, bowel disorders (without IBD) and epilepsy did not change significantly. The comorbidities of ASD encompass disease states that are significantly overrepresented in ASD with respect to even the patient populations of tertiary health centers. This burden of comorbidities goes well beyond those routinely managed in developmental medicine centers and requires broad multidisciplinary management that payors and providers will have to plan for.
登录
查看更多内容
影响因子：
11
作者：
通讯作者：
--
影响因子：
8.2
作者：
Forsén, L;Meyer, HE;Edna, TH
通讯作者：
Edna, TH
DOI：
10.1097/dbp.0b013e318203e06d
发表时间：
2011-01-01
影响因子：
2.4
作者：
Berlin, Kristoffer S.;Lobato, Debra J.;LeLeiko, Neal S.
通讯作者：
LeLeiko, Neal S.
影响因子：
8
作者：
Gabbay, Vilma;Coffey, Barbara J.;Rabinovitz, Beth
通讯作者：
Rabinovitz, Beth
影响因子：
2.8
作者：
Campbell, Peter G.;Malone, Jennifer;Ratliff, John K.
通讯作者：
Ratliff, John K.